Differentiating vasculitis from other diseases: Difference between revisions

	Vasculitis
Overview
Classification Large-sized vessel vasculitis Takayasu's Arteritis Temporal Arteritis Medium-sized vessel vasculitis Kawasaki's Disease Polyarteritis Nodosa Small-sized vessel vasculitis Churg-Strauss Syndrome Cutaneous leukocytoclastic vasculitis Essential cryoglobulinemic vasculitis Henoch-Schonlein Purpura Microscopic polyangiitis Wegener's Granulomatosis Variable-sized vessel vasculitis Sjogren syndrome Cogan syndrome Single organ vasculitis Primary central nervous system angiitis
Causes
Differential Diagnosis

VisualWikitext

Revision as of 20:26, 22 March 2018

gsEditor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:

Overview

Differential Diagnosis

Abbreviations: ABG= Arterial blood gas, ANP= Atrial natriuretic peptide, BNP= Brain natriuretic peptide, CBC= Complete blood count, COPD= Chronic obstructive pulmonary disease, CRP= C-reactive protein, CT= Computed tomography, CXR= Chest X-ray, DVT= Deep vein thrombosis, ESR= Erythrocyte sedimentation rate, HRCT= High Resolution CT, IgE= Immunoglobulin E, LDH= Lactate dehydrogenase, PCWP= Pulmonary capillary wedge pressure.

			Symptoms					Physical examination			Lab Findings				Imaging				Histopathology
Diseases			Clinical manifestations								Para-clinical findings									Gold standard	Additional findings
			Symptoms					Physical examination			Para-clinical findings
			Headache	Fever	Weight loss	Arthralgia	Claudication	Bruit	HTN	Focal neurological disorder	Biomarker	CBC	ESR	Other	CT scan	Angiography	Ultrasound	Other	Histopathology
Large-Vessel Vasculitis	Takayasu arteritis^[1]		+	+/-	+	-	+	+	+/-	+/-	ESR	Leukocytosis, Anemia	↑	CRP	Aneurysmal dilatation of the aorta	Blood vessel stenosis	Circumferential thickening of the arterial wall (Macaroni sign)	PET-scan, Cardiac CT	Granulomatous inflammation of arteries	Arteriography	Coronary aneurysm
	Giant cell arteritis^[2]		+	-	+	+/-	-	-	-	+/-	ESR	Normal	↑	CRP	Stenosis, Occlusion, Dilatation	Aneurysm	-	Mural inflammation in MRA	Granulomatous inflammation of arteries	Biopsy	Jaw pain and claudication
	Neurological disease	Cerebral aneurysm^[3]	+	-	-	-	-	-	+/-	+	-	Normal	Normal	-	Well-defined round, slightly hyperattenuating lesion	Bulging out of the main lumen	-	Heterogeneous signal intensity in MRA	Layers of smooth muscle cells, Intact endothelium	Digital subtraction angiography (DSA)	Nausea, Vomiting
		Neurofibromatosis type 1^[4]	+/-	-	+/-	-	-	-	+	+	NF1 mutated gene	Normal	Normal	Neurofibromin gene	Bone abnormalities	Optical coherence tomography angiography (OCTA)	-	Optic nerve gliomas in MRI	Elongated spindle-shaped cells in neurofibromas		Cafe au Lait spot
		Neurofibromatosis type 2	+/-																		Hearing loss, Vision loss
	Systemic disease	Fibromuscular dysplasia
		Ehlers-Danlos syndrome
		Polymyalgia rheumatica (PMR)
		Amyloidosis
Medium-Vessel Vasculitis	Polyarteritis nodosa
	Hepatitis B virus-associated polyarteritis nodosa
	Kawasaki disease
	Infectious disease	Parvovirus B19 infection
		Scarlet fever
		Toxic shock syndrome
		Mononucleosis
		Leptospirosis
		Lyme Disease
		Measles
		Rocky Mountain Spotted Fever
		Staphylococcal Scalded Skin Syndrome
		Toxic Epidermal Necrolysis
	Cardiovascular disease	Atrial Myxoma
		Cholesterol Embolism
		Segmental arterial mediolysis
	Systemic disease	Antiphospholipid Syndrome
	Systemic disease	Juvenile Idiopathic Arthritis
Small-Vessel Vasculitis	ANCA-associated vasculitis	Microscopic polyangiitis
		Granulomatosis with polyangiitis (Wegener’s)
		Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
		Hydralazine-associated ANCA-associated vasculitis
	Immune complex small-vessel vasculitis	Anti-glomerular basement membrane disease
		Cryoglobulinemic vasculitis
		Hepatitis C virus-associated cryoglobulinemic vasculitis
		IgA vasculitis (Henoch-Schönlein purpura)
		Hypocomplementemic urticarial vasculitis (anti-C1q vasculitis)
	Gastrointestinal disease	Acute mesenteric ischemia
	Cardiovascular disease	Infective Endocarditis
	Cardiovascular disease	Leukocytoclastic Vasculitis
	Pulmonary disease	Langerhans Cell Histiocytosis
		Lung Abscess
		Non-Small Cell Lung Cancer
		Small Cell Lung Cancer
		Asthma
		Pulmonary Infarction
	Renal disease	Acute Poststreptococcal Glomerulonephritis
	Hematologic disease	Hemolytic-Uremic Syndrome
		Chronic Lymphocytic Leukemia (CLL)
		Multiple Myeloma
		Hypereosinophilic Syndrome
		Non-Hodgkin Lymphoma
		Serum Sickness
		Disseminated Intravascular Coagulation
		Idiopathic Thrombocytopenic Purpura
		B cell lymphoproliferative disorder
	Systemic disease	Sarcoidosis
		Legionella Infection
		Systemic lupus erythematosus
		Rheumatoid arthritis
		Relapsing polychondritis
Variable-vessel vasculitis	Behçet’s syndrome
	Cogan's syndrome
	Gastrointestinal disease	Inflammatory Bowel Disease
		Whipple's disease
		Sjögren's syndrome
Single-organ vasculitis	Primary central nervous system vasculitis
	Infectious disease	Aspergillosis
		Histoplasmosis
		Herpes Simplex Encephalitis
	Systemic disease	Eclampsia
	Systemic disease	Fibromuscular Dysplasia

References

↑ Vaideeswar P, Deshpande JR (2013). "Pathology of Takayasu arteritis: A brief review". Ann Pediatr Cardiol. 6 (1): 52–8. doi:10.4103/0974-2069.107235. PMC 3634248. PMID 23626437.
↑ Calvo-Romero JM (2003). "Giant cell arteritis". Postgrad Med J. 79 (935): 511–5. PMC 1742823. PMID 13679546.
↑ Stafa A, Leonardi M (2008). "Role of neuroradiology in evaluating cerebral aneurysms". Interv Neuroradiol. 14 Suppl 1: 23–37. doi:10.1177/15910199080140S106. PMC 3328052. PMID 20557771.
↑ Cassiman C, Casteels I, Stalmans P, Legius E, Jacob J (2017). "Optical Coherence Tomography Angiography of Retinal Microvascular Changes Overlying Choroidal Nodules in Neurofibromatosis Type 1". Case Rep Ophthalmol. 8 (1): 214–220. doi:10.1159/000469702. PMC 5422752. PMID 28512424.

Template:WH Template:WS

[pmid23626437-1] Vaideeswar P, Deshpande JR (2013). "Pathology of Takayasu arteritis: A brief review". Ann Pediatr Cardiol. 6 (1): 52–8. doi:10.4103/0974-2069.107235. PMC 3634248. PMID 23626437.

[pmid13679546-2] Calvo-Romero JM (2003). "Giant cell arteritis". Postgrad Med J. 79 (935): 511–5. PMC 1742823. PMID 13679546.

[pmid20557771-3] Stafa A, Leonardi M (2008). "Role of neuroradiology in evaluating cerebral aneurysms". Interv Neuroradiol. 14 Suppl 1: 23–37. doi:10.1177/15910199080140S106. PMC 3328052. PMID 20557771.

[pmid28512424-4] Cassiman C, Casteels I, Stalmans P, Legius E, Jacob J (2017). "Optical Coherence Tomography Angiography of Retinal Microvascular Changes Overlying Choroidal Nodules in Neurofibromatosis Type 1". Case Rep Ophthalmol. 8 (1): 214–220. doi:10.1159/000469702. PMC 5422752. PMID 28512424.

[1]

[2]

[3]

[4]

@@ Line 14: / Line 14: @@
 ! colspan="3" rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |Diseases
 | colspan="8" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |'''Clinical manifestations'''
-! colspan="8" rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Para-clinical findings
+! colspan="9" rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Para-clinical findings
 | colspan="1" rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |'''Gold standard'''
 ! rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |Additional findings
@@ Line 23: / Line 23: @@
 ! colspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |Lab Findings
 ! colspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |Imaging
+! rowspan="2" |Histopathology
 |-
 ! style="background:#4479BA; color: #FFFFFF;" align="center" |Headache
@@ Line 46: / Line 47: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
@@ Line 59: / Line 60: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Circumferential thickening of the [[arterial]] wall (Macaroni sign)
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[PET scan|PET-scan]], [[Cardiac]] [[CT]]
+![[Granulomatous]] [[inflammation]] of [[arteries]]
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Arteriography]]
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Coronary aneurysm]]
 |-
-! colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Giant cell arteritis]]
+! colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Giant cell arteritis]]<ref name="pmid13679546">{{cite journal| author=Calvo-Romero JM| title=Giant cell arteritis. | journal=Postgrad Med J | year= 2003 | volume= 79 | issue= 935 | pages= 511-5 | pmid=13679546 | doi= | pmc=1742823 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=13679546  }}</ref>
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[ESR]]
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[CRP]]
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Stenosis]], [[Occlusion]], [[Dilatation]]
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Aneurysm]]
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Mural [[inflammation]] in [[Magnetic resonance angiography|MRA]]
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+![[Granulomatous]] [[inflammation]] of [[arteries]]
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Biopsy]]
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Jaw pain]] and [[Jaw claudication|claudication]]
 |-
 ! rowspan="3" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Neurological disease]]
-! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cerebral aneurysm]]
+! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cerebral aneurysm]]<ref name="pmid20557771">{{cite journal| author=Stafa A, Leonardi M| title=Role of neuroradiology in evaluating cerebral aneurysms. | journal=Interv Neuroradiol | year= 2008 | volume= 14 Suppl 1 | issue=  | pages= 23-37 | pmid=20557771 | doi=10.1177/15910199080140S106 | pmc=3328052 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20557771  }}</ref>
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Well-defined round, slightly hyperattenuating lesion
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Bulging out of the [[Lumen|main lumen]]
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Heterogeneous]] signal intensity in [[Magnetic resonance angiography|MRA]]
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!Layers of [[smooth muscle cells]], Intact [[endothelium]]
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Digital subtraction angiography|Digital subtraction angiography (DSA)]]
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Nausea]], [[Vomiting]]
 |-
-! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Neurofibromatosis type 1]]
+! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Neurofibromatosis type 1]]<ref name="pmid28512424">{{cite journal| author=Cassiman C, Casteels I, Stalmans P, Legius E, Jacob J| title=Optical Coherence Tomography Angiography of Retinal Microvascular Changes Overlying Choroidal Nodules in Neurofibromatosis Type 1. | journal=Case Rep Ophthalmol | year= 2017 | volume= 8 | issue= 1 | pages= 214-220 | pmid=28512424 | doi=10.1159/000469702 | pmc=5422752 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28512424  }}</ref>
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[NF1|NF1 mutated gene]]
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Neurofibromin|Neurofibromin gene]]
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Bone disease|Bone abnormalities]]
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Optical coherence tomography angiography (OCTA)
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Optic nerve gliomas]] in [[MRI]]
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!Elongated spindle-shaped [[cells]] in [[Neurofibroma|neurofibromas]]
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Café au lait spot|Cafe au Lait spot]]
 |-
 ! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Neurofibromatosis type 2]]
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 139: / Line 145: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Hearing loss]], [[Vision loss]]
-! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 |-
 ! rowspan="4" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Systemic disease]]
@@ Line 161: / Line 167: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 181: / Line 188: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 201: / Line 209: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 221: / Line 230: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 242: / Line 252: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 262: / Line 273: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 282: / Line 294: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 303: / Line 316: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 323: / Line 337: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 343: / Line 358: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 363: / Line 379: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 383: / Line 400: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 403: / Line 421: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 423: / Line 442: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 443: / Line 463: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 463: / Line 484: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 483: / Line 505: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 504: / Line 527: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 524: / Line 548: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 544: / Line 569: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 565: / Line 591: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 585: / Line 612: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 607: / Line 635: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 627: / Line 656: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 647: / Line 677: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 667: / Line 698: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 688: / Line 720: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 708: / Line 741: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 728: / Line 762: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 748: / Line 783: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 768: / Line 804: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 789: / Line 826: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 810: / Line 848: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 830: / Line 869: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 851: / Line 891: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 871: / Line 912: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 891: / Line 933: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 911: / Line 954: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 931: / Line 975: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 951: / Line 996: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 972: / Line 1,018: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 993: / Line 1,040: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 1,013: / Line 1,061: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 1,033: / Line 1,082: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 1,053: / Line 1,103: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 1,073: / Line 1,124: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 1,093: / Line 1,145: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 1,113: / Line 1,166: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 1,133: / Line 1,187: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 1,153: / Line 1,208: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 1,174: / Line 1,230: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 1,194: / Line 1,251: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 1,214: / Line 1,272: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 1,234: / Line 1,293: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 1,254: / Line 1,314: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 1,275: / Line 1,336: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 1,295: / Line 1,357: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 1,316: / Line 1,379: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 1,336: / Line 1,400: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 1,356: / Line 1,421: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 1,377: / Line 1,443: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 1,398: / Line 1,465: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 1,418: / Line 1,486: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 1,438: / Line 1,507: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 1,459: / Line 1,529: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
@@ Line 1,479: / Line 1,550: @@
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
+!
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 ! style="padding: 5px 5px; background: #F5F5F5;" align="center" |

Differentiating vasculitis from other diseases: Difference between revisions

Revision as of 20:26, 22 March 2018

Overview

Differential Diagnosis

References

Navigation menu